## REMARKS

Claims 1-13 and 15-32 have been canceled without prejudice. Accordingly, the claims pending and under consideration are 33-37.

In the office action, restriction was required under 35 U.S.C. 121 to one of the following:

- I. Claims 1-13, 15-32, drawn to compounds, composition and method of use (+)-norcisapride
- II. Claims 33-37, drawn to method of accelerating intestinal cleansing using multiple active ingredients

Applicants hereby elect the subject matter of Group II, that is, claims 33-37 drawn to method of accelerating intestinal cleansing using multiple active ingredients.

In the Office Action, if Group II is elected, a further election of a single disclosed combination of active ingredients with every element named is also required.

In response thereto, applicants elect the combination of claim 37.

Applicants reserve the right to file divisional applications directed to the canceled nonelected subject matter at the appropriate time.

In the Office Action, Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 C.F.R. 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Applicants submit herewith a request under 37 C.F.R. 1.48(b) and the required fee.

Serial No. 10/807,035

Applicants respectfully request an early allowance and notice thereof.

Respectfully submitted,

By: \_\_/Ellen Ciambrone Coletti/\_\_\_ Ellen Ciambrone Coletti Reg. No. 34,140

Johnson & Johnson One Johnson & Johnson Plaza New Brunswick, NJ 08933-7003 (732) 524-2359

Dated: March 17, 2006